ResMed vs Intuitive Surgical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ResMed Inc (RMD)

Q3 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

August 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Latest7 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Intuitive Surgical Inc (ISRG)

Q3 202629 Jun – 15 Sep 2026

▼3▲1

Intuitive Surgical Beats Q2, But Growth Slows and Competition Heats Up

Q2 Earnings Beat and Strong Recurring Revenue Intuitive Surgical beat Q2 2026 expectations with 19% revenue growth to $2.89 billion and 16% worldwide procedure growth. About 85% of sales are recurring, providing steady income. Free cash flow jumped 71% to $1.8 billion, supporting buybacks and new approvals.
This is the main positive force behind the stock this quarter, showing strong financial performance and cash generation.
U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% due to ACA subsidy expirations and GLP-1-driven bariatric declines. This deceleration raises concerns about future growth, making the stock sensitive to any further slowdown headlines.
This is a key negative factor that pressured the stock and highlights a real counterweight to the strong overall results.
Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units and tariff threats pressured margins and shares. These issues add costs and uncertainty, weighing on investor sentiment and profitability.
This is a new negative event that directly impacted margins and stock performance during the quarter.
Intensifying Competition from J&J's Ottava Johnson & Johnson's FDA-approved Ottava robot intensifies competition in robotic surgery. This threatens Intuitive Surgical's market share and pricing power, adding pressure on future growth and the stock.
This is a new competitive development that could erode Intuitive Surgical's dominance and affect long-term growth.

August 202629 Jun – 15 Sep 2026

▲2▼1

Intuitive Surgical Gains on Procedure Growth, Ion Surge, and New Approvals

Strong Procedure and System Growth Worldwide procedures rose 16% and system placements jumped 18% to 468, showing robust demand for da Vinci robots. Recurring revenue now makes up about 85% of sales, providing a steady income base.
This highlights the core operational momentum that drove the stock.
Ion Platform Surge and Cash Flow Growth The Ion platform grew 36%, free cash flow climbed 71% to $1.8 billion, and buybacks plus new approvals like the CE mark for da Vinci SP support growth. Analysts upgraded the stock, and a new Malaysia plant expands Asian capacity.
These are new positive developments that boosted investor confidence.
Rising Competition and U.S. Slowdown Concerns Rising robot competition and concerns about a U.S. slowdown could pressure growth. The stock remains sensitive to any deceleration in headline growth despite its durable recurring-revenue base.
This is the main risk that could weigh on the stock.

Latest29 Jun – 15 Sep 2026

▲4

Intuitive Surgical: Procedure Growth, New Approvals, and Cash Strength Drive Upside

Procedure Growth and System Placements Accelerate Worldwide procedures rose 16% and da Vinci system placements jumped 18% to 468, with U.S. placements up 24%. This shows hospitals are still buying and using Intuitive's robots, which drives recurring revenue and future sales. The stock benefits because growth is durable despite concerns about a U.S. slowdown.
This is the core demand driver that directly supports revenue and earnings growth, which pushes the stock up.
Ion Platform Emerges as Second Growth Engine Ion procedures surged 36% to 48,000, cumulative procedures passed 400,000, and the installed base grew 21% annually. This new lung-cancer diagnosis platform gives Intuitive another source of recurring revenue, reducing reliance on da Vinci and supporting a higher stock valuation.
It highlights a new, fast-growing revenue stream that diversifies the business and boosts long-term growth prospects.
Record Cash Flow Fuels Innovation and Buybacks First-half free cash flow jumped 71% to $1.8 billion, and the company bought back $379 million of stock. Strong cash gives Intuitive flexibility to invest in R&D, expand manufacturing, and return money to shareholders, which supports the stock price by signaling financial health and confidence.
It shows the company's financial strength and ability to fund growth without sacrificing shareholder returns, a key positive for the stock.
Clinical Evidence and New Regulatory Approval Expand Use A landmark meta-analysis showed da Vinci surgery improves outcomes across 13 conditions, and a new CE mark allows transvaginal gynecology with da Vinci SP in Europe. These strengthen the case for adoption, open new markets, and support premium pricing, all of which can lift the stock.
It provides scientific validation and regulatory expansion that can drive broader adoption and pricing power, directly impacting future revenue.

3 Aug – 19 Aug 2026

▲3

ISRG: Solid Procedure Growth and New Products Offset Rising Robot Competition

Recurring revenue and procedure growth remain strong Worldwide procedures rose about 16% and system placements jumped 18% to 468, with recurring instrument and service revenue now roughly 85% of sales. That steady, repeat business supports ISRG's price even when headline growth slows.
Shows the core demand engine still growing, the main support for the stock.
Analyst upgrades and software moat reinforce confidence Oppenheimer upgraded ISRG to Outperform with a $500 target, and UBS called the selloff overdone. The company is rolling out 100+ da Vinci 5 software updates and filed for FDA clearances, deepening its technology lead and supporting the stock.
New analyst actions and product roadmap directly lift investor sentiment and the stock.
New Malaysia plant expands supply for Asia growth ISRG will build a 316,000-square-foot manufacturing facility in Penang, Malaysia, starting operations in 2028 and creating 1,200 jobs. This adds capacity for surgical instruments and supports long-term growth in Asia Pacific, a positive for the stock.
New capacity investment signals confidence and future supply expansion.

July 20261 Jul – 31 Jul 2026

▼3▲1

Intuitive Surgical Q2 Beat Marred by Recall, Slowdown, and New Rival

Q2 Beat and Procedure Growth Intuitive Surgical beat Q2 2026 expectations with revenue up 19% to $2.89 billion, adjusted EPS of $2.80, and 16% worldwide procedure growth. This drove recurring instrument and service revenue, supporting the stock.
This is the main positive fundamental driver for the period.
U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% as ACA subsidy expirations left patients uninsured, and GLP-1 drugs reduced bariatric surgeries. This weighed on overall growth and investor sentiment.
This explains a key negative trend affecting demand.
Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units raised regulatory and cost concerns, sending shares down 6.3%. Tariffs also threaten margins, with management warning they could materially alter results.
These are major negative events that pressured the stock.
Competition from J&J's Ottava J&J's FDA-approved Ottava robot now directly challenges da Vinci, threatening market share and pricing power. This competitive threat adds to concerns about future growth.
This is a new competitive development with negative implications.

20 Jul – 31 Jul 2026

▼4

ISRG Plunges on Slowing US Procedures, GLP-1 Headwinds, and New J&J Competition

US Procedure Growth Slows on Insurance and GLP-1 US da Vinci procedure growth slowed to 12% from 14% as ACA subsidy expirations left patients uninsured and GLP-1 weight-loss drugs cut bariatric surgeries. This reduces recurring revenue from instruments and services, pressuring ISRG's stock.
This is the core reason for the stock's decline and the main new negative driver this period.
J&J's Ottava Robot Enters US Market Johnson & Johnson received FDA approval for its Ottava surgical robot, directly challenging Intuitive's da Vinci in soft-tissue surgery. This raises competition and could limit ISRG's market share and pricing power, weighing on the stock.
A new competitive threat that changes the long-term outlook for ISRG's dominance.
Full-Year Procedure Growth Guided to Middle of Range Management said full-year procedure growth will likely be near the middle of its 13.5-15.5% range, not the high end. This disappointed investors who expected stronger growth, leading to a sharp sell-off.
Guidance cut is a key new negative catalyst that drove the stock down.
Tariff Headwinds Could Materially Alter Results Intuitive warned that additional tariffs could materially alter its financial results, adding cost pressure. Tariffs raise expenses for imported components, which can squeeze profit margins and reduce earnings.
Tariff risk is a new explicit warning that adds uncertainty to future profits.

1 Jul – 17 Jul 2026

▼3▲1

Intuitive Beats Q2 but Insurance and Tariff Worries Sink Shares

Q2 Beat on Procedure Growth and da Vinci 5 Placements Intuitive reported Q2 revenue of $2.89 billion, up 19%, and adjusted EPS of $2.80, both beating expectations. Worldwide procedures grew 16%, with 246 da Vinci 5 systems placed. More procedures and system placements drive recurring instrument and service revenue, directly boosting ISRG's sales and profit.
This is the core new financial result that shows the company's underlying business is still growing strongly.
U.S. Procedure Growth Slows on Insurance Changes U.S. da Vinci procedure growth slowed to 12% as patients lost health insurance after ACA tax credits expired. Management warned this could weigh on demand, and analysts cut price targets. Slower U.S. procedure growth means less recurring revenue from instruments and services, pressuring ISRG's stock.
This is the main new negative that caused the stock to drop over 9% despite the earnings beat.
Class II Recall of da Vinci Components Intuitive issued a voluntary Class II recall of certain da Vinci components due to an E-brake retainer pin issue, affecting 454 units. The recall raises operational and regulatory scrutiny, and the stock fell 6.3% on the news. It adds uncertainty ahead of earnings and could lead to higher costs or reputational damage.
This is a new negative event that directly hit the stock price and raises questions about product quality and regulatory risk.
Tariff-Related Margin Pressure Flagged Intuitive maintained its full-year procedure growth outlook of 13.5-15.5% but flagged tariff-related margin pressure. Tariffs add costs to imported components, which can squeeze profit margins. The company also noted a $28 million tariff refund benefit this quarter, but future tariffs remain a headwind.
This is a new cost concern that weighs on profitability and was cited as a reason for the stock's decline.

Q2 202618 Jun – 25 Jun 2026

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.
This is a new, concrete positive catalyst that directly affects future revenue and earnings.
Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.
This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.
AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.
This is a new angle on how ISRG leverages technology to defend its market leadership.
Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.
This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

June 202618 Jun – 25 Jun 2026

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.
This is a new, concrete positive catalyst that directly affects future revenue and earnings.
Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.
This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.
AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.
This is a new angle on how ISRG leverages technology to defend its market leadership.
Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.
This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

18 Jun – 25 Jun 2026

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.
This is a new, concrete positive catalyst that directly affects future revenue and earnings.
Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.
This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.
AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.
This is a new angle on how ISRG leverages technology to defend its market leadership.
Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.
This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.